UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39460 KYMERA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter ...

Kymera Therapeutics (NASDAQ:KYMR) Q2 2023 Earnings Conference Call August 3, 2023 9:00 AM ET Company Participants Bruce Jacobs - CFO Nello Mainolfi - Founder, President and CEO Jared Gollob - CMO Justine Koenigsberg - VP, IR Conference Call Participants Marc Frahm - TD Cowen Brad Canino - Stifel Chris Shibutani - Goldman Sachs Michael Schmidt - Guggenheim Kalpit Patel - B. Riley Securities Vikram Purohit - Morgan Stanley Eric Joseph - JPMorgan Srikripa Devarakonda - Truist Securities Derek Archila - Wells F ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39460 KYMERA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or organization) 200 Arsenal Yards Blvd., Suite 230 Watertown, Massachusetts 02472 (Address of ...

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Bruce Jacobs - Chief Financial Officer Nello Mainolfi - Founder, President and CEO Jared Gollob - Chief Medical Officer Conference Call Participants Michael Schmidt - Guggenheim Brad Canino - Stifel Chris Shibutani - Goldman Sachs Marc Frahm - TD Cowen Mike Kratky - SVB Timur Ivannikov - Raymond James Kalpit Patel - B. Riley Operator Good morning, and welcome to the Kymera Therapeutics First Q ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39460 KYMERA THERAPEUTICS, INC. 200 Arsenal Yards Blvd., Suite 230 Watertown, Massachuset ...

HS (n=13) AD (n=8) Patients with any prior Therapy, n (%) Antibiotics/Antibacterials** Corticosteroids Adalimumab Other Biologics Patient Disposition Completed 12 • 9 Moderate • 1 Severe • 2 Very Severe * Withdrew treatment after 4 doses for personal reasons ** Withdrew treatment after 5 doses for personal reasons KT-474 PK at the 75 mg QD dose (fed state) in patients is comparable to 100 mg QD (fasted state) in HV IRAK4 Levels in PBMC in Patients at Day 28 (MS) AD Patients (Baseline) M ean ( ±SE) IRA K4 Le ...

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET Company Participants Bruce Jacobs - Chief Financial Officer Nello Mainolfi - Founder & Chief Executive Officer Jared Gollob - Chief Medical Officer Conference Call Participants Eric Joseph - JPMorgan Bradley Canino - Stifel Vikram Purohit - Morgan Stanley Paul Jeng - Guggenheim Securities Marc Frahm - Cowen and Company Michael Kratky - SVB Securities Andrew Fleszar - B. Riley Securities Zhiqiang Shu - Ber ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) (Address of principal executive offices) (Zip Code) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39460 KYMERA THERAPEUTICS, INC. (Exact name of Registrant as specified in its Cha ...

• Large opportunity in wide variety of cancers MDM2 CRISPR Sensitivity Score Graph generated with data obtained from DepMap.org 0.6 0.4 0.2 0 -0.2 -0.4 -0.6 -0.8 -1 -1.2 -1.4 -1.6 -1.8 -2 -2.2 p53MUT p53WT Cell Line p53 Degrader Inhibitor p53 ub ub ub MDM2 MDM2 p53 Degradation p53 Targets p53 Feedback Loop Tumor Suppression Apoptosis (Noxa, Bax, Puma) DNA Damage Hypoxia Oncogenes Other • MDM2 small molecule inhibitors of MDM2/p53 interaction show activity in the clinic.. Degrader Advantage • MDM2 degrader c ...

INVENTING NEW MEDICINES W I T H T A R G E T E D P R O T E I N D E G R A D A T I O N November 2022 Forward-looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. These statements include information about our current and future prospects and our operations and financial results, which are based on currently available information. All statements other than statements of histo ...